drugset / Trial / NCT01459796

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

NCT01459796

Phase 3 Terminated 220 enrolled Regeneron Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study was to determine the safety and tolerability of rilonacept for participants with gout who were initiating allopurinol.

Timeline

Start
2011-11
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilonacept Protein / enzyme biologic 80 mg Subcutaneous
Background Allopurinol Small molecule 50 mg Oral
Background Allopurinol Small molecule 100 mg Oral

Indications